相关实验视频
Updated: Aug 16, 2026

10:43
Modeling Oral-Esophageal Squamous Cell Carcinoma in 3D Organoids
Published on: December 23, 2022
3.3K
在食道状细胞癌中基于代谢途径的集群的遗传和分子特征
Ze Wang1,2, Yuan Zhang1, Xiaorong Yang1
1Clinical Epidemiology Unit, Clinical Research Center of Shandong University, Qilu Hospital of Shandong University, Jinan, 250012, Shandong, China.
Scientific reports
|March 15, 2024
概括
食道状细胞癌 (ESCC) 亚型表现出不同的代谢特征. 能量代谢亚型 (MPC3) 是积极的,对化疗的反应比免疫疗法更好.
科学领域:
- 在瘤学瘤学.
- 代谢学 代谢学 代谢学
- 癌症生物学 癌症生物学
背景情况:
- 食道状细胞癌 (ESCC) 是一种具有攻击性的癌症,其中代谢重编程至关重要.
- 了解代谢异质性是开发ESCC向治疗的关键.
研究的目的:
- 根据代谢途径对ESCC亚型进行分类.
- 为了研究不同ESCC亚型的代谢概况和治疗敏感性.
主要方法:
- 来自Reactome数据库的代谢途径的无监督集群分析.
- 液体染色学-质谱学 (LC-MS) 用于代谢物分析.
- 对免疫疗法和化疗的药物敏感性评估.
主要成果:
- 确定了三个ESCC亚型:MPC1 (脂质),MPC2 (氨基酸) 和MPC3 (能量代谢).
- MPC3亚型表现出高水平的糖解,增加的攻击性和较差的生存率.
- MPC3对多拉玛皮莫德化疗有敏感性,但对PD-L1免疫疗法反应不佳.
结论:
- ESCC表现出显著的代谢异质性,定义了不同的患者亚型.
- 代谢分析可以预测攻击性,并指导ESCC的个性化治疗策略.
- 针对特定的代谢途径为新的ESCC疗法提供了一个有希望的途径.
相关概念视频
Cancer
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

